Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | S100B | P04271 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11736864 | 0.98 | IP6K1 (0.71) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL10739901 | 0.87 | MAPT (0.59) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL340945 | 0.86 | PRKDC (0.67) | IP6K1MAPTALDH1A1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL3503462 | 0.86 | MAPT (0.58) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL8976368 | 0.85 | IP6K1 (1.00) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL7673611 | 0.85 | IP6K1 (0.76) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL6288053 | 0.84 | IP6K1 (0.54) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL8871236 | 0.83 | IP6K1 (0.97) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL2060966 | 0.83 | IP6K1 (0.73) | IP6K1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL17779230 | 0.83 | IP6K1 (0.68) | IP6K1MAPTALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872822-B2 | Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition | L'OREAL (FR) | 2018-01-23 | — | — | US | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | L'OREAL (FR) | 2016-05-26 | — | — | US | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-4053470-A | BACTERICIDES, ANTIBIOTICS | PARKE, DAVIS & COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3954734-A | PENICILLIN AND CEPHALOSPORIN TYPE | PARKE, DAVIS & COMPANY | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143826-A1 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION | KRT18, ARSA, SQOR | IP6K1 4489/4885MAPT 2197/4885ALDH1A1 440/4885 |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | IP6K1 3153/4885MAPT 4760/4885ALDH1A1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.